Table 3.
Type | Symbol | Theme | Relevant figure | Supporting cluster(s) |
---|---|---|---|---|
Chemical-gene | A+ | Agonism, activation | 3a | 6+ |
A− | Antagonism, blocking | 6– | ||
B | Binding, ligand (esp. receptors) | 14–16 | ||
E+ | Increases expression/production | 8+, 9+ | ||
E− | Decreases expression/production | 8–, 9–, 10 | ||
E | Affects expression/production (neutral) | 8, 9, 11a | ||
N | Inhibits | 3 | ||
Gene-chemical | O | Transport, channels | 3a | 19, 21 |
K | Metabolism, pharmacokinetics | 11c | ||
Z | Enzyme activity | 20 | ||
Chemical-disease | T | Treatment/therapy (incl. investigatory) | 3b | 8g, 8h, 9 |
C | Inhibits cell growth (esp. cancers) | 2, 3 | ||
Sa | Side effect/adverse event | 6, 15, 16 | ||
Pr | Prevents, suppresses | 1, 9, 21, 24, 28 | ||
Pa | Alleviates, reduces | 26, 30 | ||
J | Role in pathogenesis | 20 | ||
Disease-chemical | Mp | Biomarkers (progression) | 3b | 18, 19 |
gene-disease | U | Causal mutations | 3c | 14 |
Ud | Mutations affect disease course | 13 | ||
D | Drug targets | 10, 12 | ||
J | Role in pathogenesis | 2h, 4, 6, 8, 9 | ||
Te | Possible therapeutic effect | 2j, 3 | ||
Y | Polymorphisms alter risk | 22, 26, 27 | ||
G | Promotes progression | 29 | ||
Disease-gene | Md | Biomarkers (diagnostic) | 3c | 5, 7 |
X | Overexpression in disease | 15, 17, 30 | ||
L | Improper regulation linked to disease | 18, 19, 21 | ||
Gene–gene | B | Binding, ligand (esp. receptors) | 3d | 10 |
W | Enhances response | 13 | ||
V+ | Activates, stimulates | 14, 16 | ||
E+ | Increases expression/production | 21, 22 | ||
E | Affects expression/production (neutral) | 7, 17 | ||
I | Signaling pathway | 24 | ||
H | Same protein or complex | 25 | ||
Rg | Regulation | 28, 30 | ||
Q | Production by cell population | 1, 2, 6 |
Note: A symbol is bolded if it refers to a theme that appears in multiple dendrograms. Complete descriptions of the individual clusters can be found in the Discussion. Examples of dependency paths from each cluster are in the Supplementary Material for this article.